Judy Black, Chair: Ms. Black is a Policy Director in the Government Relations Department of Brownstein, Hyatt, Farber and Schreck. She is recognized as one of the premier Republican lobbyists in Washington, DC, while also enjoying bipartisan relationships and respect throughout the federal government. For over a decade Ms. Black has helped Fortune 500 companies, leading non-profits, and industry trade groups navigate and participate in the public policy process. Prior to joining the firm, Ms. Black co- owned and operated Evans and Black Capitol Strategies, a DC-based legislative and lobbying firm. Ms. Black has also served as the senior vice president of government relations for Ticketmaster, where she established the company’s government relations office and directed all federal and state government affairs. Additionally, she held the position of senior vice president of government relations for the International Council of Shopping Centers.
Ms. Black served in the White House from 1987 to 1989, where she was the Special Assistant to President Reagan for Intergovernmental Affairs. In that capacity, she was the liaison to the nation’s governors and other statewide elected officials. Ms. Black has also held positions as the secretary for the Republican National Convention (1984), a Reagan delegate at the 1984 Republican National Convention, and treasurer for the National Federation of Republican Women (1986-1987). In the 2008 presidential campaign, she volunteered as cochairman of Women for McCain. Acknowledging her experience, Ms. Black was asked in the 2012 presidential campaign to volunteer as Chairman of Women for Romney in Washington, DC.
Kenneth G. Saag, MD, MSc, President: Dr. Saag is Jane Knight Lowe Professor of Medicine, Division of Clinical Immunology and Rheumatology, at the University of Alabama at Birmingham (UAB) School of Medicine, and Professor of Epidemiology, at the UAB School of Public Health. He is the founding Director of the Deep South Musculoskeletal (DSM) Center for Education and Research on therapeutics (CERTs), and Associate Director of the Multidisciplinary Clinical Research Center (NIAMS P60). Dr. SSaag is also Director of the UAB Center for Outcomes and Effectiveness Research and Education (COERE), a university-wide supported interdisciplinary research center. He is the director of the Agency for Healthcare, Research and Quality (AHRQ) supported UAB T32 in Health Services Research. He is a practicing rheumatologist and outcomes researcher with expertise in musculoskeletal disorders (MSD) and pharmacoepidemiology, and has a clinical focus in bone health. He is the only rheumatologist on the Board of Directors of the National Osteoporosis Board or Trustees.
Dr. Saag is experienced in designing and conducting clinical trials in the therapeutics of MSD and in population-based investigations, working with large databases, and quality indicator development. He is has served on the FDA Arthritis Advisory Committee and co-chaired the American Medical Association (AMA) Physician Consortium for Performance Improvement on Osteoporosis. He is on the editorial board of Annals of Internal Medicine, Associate Editor for Arthritis Research and Therapy, and serves as the American College of Rheumatology (ACR), Quality of Care Committee Chair. Dr. Saag has previously chaired the Arthritis Foundation Clinical, Therapeutics and Outcomes Study Section, has served on several NIH study sections, IOM Committees, National Committees to develop both arthritis and osteoporosis guidelines, the Musculoskeletal Workgroup of the Cochrane Collaboration, and the NCQA workgroup on Arthritis Quality Indicators. In addition to his CERTs, Dr. Saag has a U18 from AHRQ examining the safety of biologic agents in Rheumatoid Arthritis and has previously served as the principle investigator and lead author on the 2009 ACR-funded Recommendations for the Treatment of Rheumatoid Arthritis.
Susan Greenspan, MD, Vice President: Dr. Greenspan has held multiple roles at the University of Pittsburgh since 1999, including Professor of Medicine and Director of the Osteoporosis Prevention and Treatment Center. She is also the Director of the Bone Health Program at Magee Women’s Hospital and Program Director of the Clinical Translational Research Center at the University of Pittsburgh Medical Center. Dr. Susan Greenspan received her undergraduate degree from Stanford University and her MD from Harvard Medical School, where after training in Endocrinology and Geriatrics, she joined the faculty and founded and directed the Osteoporosis Center.
Dr. Greenspan’s NIH-funded research centers on osteoporosis in elderly men and women and has covered topics including new therapies for osteoporosis; new ways to diagnose, assess, and monitor bone loss; and bone loss in women with breast cancer and men with prostate cancer. Dr. Greenspan co-authored the U.S. Surgeon General’s report on Osteoporosis and has authored more than 150 peer reviewed articles and invited papers. She has served on the Scientific Advisory Boards for NOF and the International Society for Clinical Densitometry as well as several editorial boards of scientific journals. She was a council member of the American Society of Bone and Mineral Research from 2002-2005 and program chair for the 2006 annual meeting of the American Society of Bone and Mineral Research. She has also been featured in Best Doctors in America, Best Doctors in Pittsburgh and America’s Top Doctors.
Ann C. Miller, MD, Treasurer: Dr. Ann Miller has spent over 20 years in biopharma marketing with experience across many therapeutic areas and all phases of the product lifecycle, including in-line brands, launch products, and Phase 2 compounds. After receiving her BA and MD degrees from Duke University, Dr. Miller started her career at Merck and Co., with jobs of increasing responsibility across Medical Affairs, Business Development, and Marketing, including responsibility for the US Fosamax osteoporosis franchise. In 2002, she moved to Amgen to help build the Global Marketing function, with responsibility for the oncology franchise and, subsequently, the anemia/nephrology franchise. During this time, she received the prestigious IMPACT award for her co-leadership of a two-year, corporate- wide effort to develop and embed Amgen’s approach to marketing strategy development. In early 2006, she took over responsibility for the US osteoporosis launch of denosumab, Amgen’s key pipeline product. Dr. Miller also served as the Senior Vice President, Pharmaceutical Services, at Eisai Inc., a Japanese biopharma company with roughly $4B in US sales. Currently, she is Vice President of Marketing at Sanofi.
Dr. Miller was named a senior scholar at Duke’s Fuqua School of Business in 2008 and has been an invited speaker on Marketing for the Marketing Sciences Institute, Keck Graduate Institute, and Anderson School of Business (UCLA) Executive Education. She was elected to the National Osteoporosis Foundation Board of Trustees in 2008.
Barbara Hannah Grufferman, Secretary: Ms. Grufferman is a nationally recognized advocate for positive living. Dr. Mehmet Oz said of her previous book, The Best of Everything After 50: “Every once in a while a book comes across your desk, and you just have to pick it up. This is one of them!” She is a frequent contributor to HuffPost and AARP, has appeared on the Today Show, CBS Morning Show, Good Morning America, The Doctors, The Talk, Dr. Phil, NPR, The Dr. Oz Show on Sirius Radio and OWN, the Oprah Channel, any many local radio and TV shows. Barbara travels around the country speaking to groups on health, nutrition, career, fitness, sex and many other topics related to positive and healthy aging. She is a recipient of the Generations of Strength Award from the National Osteoporosis Foundation for her outspoken support of positive and healthy aging in America, and also serves as Bone Health Ambassador and trustee. Ms. Grufferman, a proud mother of two daughters, lives in New York City with her husband and rescued dog. A passionate knitter and runner, Ms. Grufferman has completed four New York City Marathons, one Edinburgh Marathon, and one Ultramarathon.